Former British Prime Minister David Cameron, Medical Leaders and Researchers from around the World Convene in Cleveland to Discuss Drug Development Progress

Symposium speakers included former UK Prime Minister, David Cameron, who chairs the Advisory Council for the Oxford-Harrington Rare Disease Centre — a unique transatlantic partnership between the University of Oxford, UK, and Harrington Discovery Institute at University Hospitals in Cleveland, aimed at driving breakthrough treatments for rare diseases. These diseases typically lack commercial incentive for private companies to develop therapies and treatments. Researchers often find their work at a standstill in the so-called Valley of Death — the chasm between discoveries that could not be funded and the funding sources that would not fund them.

CLEVELAND, 23/05/2025 (informazione.news - comunicati stampa - salute e benessere)

Symposium speakers included former UK Prime Minister, David Cameron , who chairs the Advisory Council for the Oxford-Harrington Rare Disease Centre — a unique transatlantic partnership between the University of Oxford , UK, and Harrington Discovery Institute at University Hospitals in Cleveland , aimed at driving breakthrough treatments for rare diseases. These diseases typically lack commercial incentive for private companies to develop therapies and treatments. Researchers often find their work at a standstill in the so-called Valley of Death — the chasm between discoveries that could not be funded and the funding sources that would not fund them.

The Advisory Council supports the OHC's mission to deliver new treatments for the estimated half a billion people affected by rare diseases worldwide. Council members are leaders of relevant industries and sectors from different regions of the world who bring expertise, resources and networks towards the initial goal of developing 40 new drugs for rare diseases in the next 10 years.

Harrington scholars presented their latest discoveries throughout the two-day scientific symposium. Of the 8,000 physician-scientists in the US, nearly 50 percent have sought support from Harrington Discovery Institute. To date 150 of those Harrington Scholars have drugs-in-the-making, more than 30 have created new companies, and four are in Phase 3 clinical trials — for heart attacks, macular degeneration, Alzheimer's, and a rare cancer syndrome. Another scholar's therapeutic for babies with spina bifida is in a potentially pivotal clinical trial.

To achieve these results, Harrington Discovery Institute created an innovation pathway consisting of creative science, drug development assistance, business strategy support, and strong management.

"    

 

View original content:https://www.prnewswire.co.uk/news-releases/former-british-prime-minister-david-cameron-medical-leaders-and-researchers-from-around-the-world-convene-in-cleveland-to-discuss-drug-development-progress-302464447.html